My ePortfolio Register   

GTX-024 for androgen receptor positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 848

Prof Beth Overmoyer - Dana-Farber Cancer Institute, Boston, USA

Prof Overmoyer speaks with ecancer at IMPAKT 2017 about results from a phase II trial of GTX-024, or enobosarm, against androgen-receptor positive breast cancer.

She describes how a new generation of androgens expand treatment options for breast cancer patients, and outlines the design and staging of trials with enobosarm.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence